With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
Floods had forced the plans in Mahad to shut down
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
Subscribe To Our Newsletter & Stay Updated
